This report is required by law (7 USC 2143). Failure to report according to the regulations can result in an order to cease and desist and to be subject to penalties as provided for in Section 21!

See attached form for additional information.

Interagency Report Control No.:

UNITED STATES DEPARTMENT OF AGRICULTURE
ANIMAL AND PLANT HEALTH INSPECTION SERVICE

ANNUAL REPORT OF RESEARCH FACILITY

(TYPE OR PRINT)

1. CERTIFICATE NUMBER: 23-R-0018
CUSTOMER NUMBER: 303

FORM APPROVED
OMB NO. 0579-0036

Wyeth Research Div Of Wyeth Pharm Inc
500 Arcola Road - D5225
Collegeville, PA 19426

Telephone: (484) -865-8054

3. REPORTING FACILITY (List all locations where animals were housed or used in actual research, testing, or experimentation, or held for these purposes. Attach additional sheets if necessary)

FACILITY LOCATIONS (Sites) - See Attached Listing

REPORT OF ANIMALS USED BY OR UNDER CONTROL OF RESEARCH FACILITY (**Attach additional sheets if necessary or use APHIS Form 7023A**)

A. Animals Covered By The Animal Welfare Regulations	B. Number of animal being bred, conditioned, or held for use in teaching, testing, experiments, research, or surgery but not ye used for such purposes.	C. Number of animals upon which teaching, research, experiments, or tests were conducted involving no pain, distress, or use o pain-relieving drugs.	D. Number of animals upon which experiments, teaching, research, surgery, or tests were conducted involving accompanying pain or distress to the animals an for which appropriate anesthetic, analgesic, or tranquilizing drugs were used.	E. Number of animals upon which teaching, experiments, research, surgery or tests were conducted involving accompanying pain or distress to the animals and for wh the use of appropriate anesthetic, analgesic, or tranquiliz drugs would have adversely affected the procedures, res or interpretation of the teaching, research, experiments, surgery, or tests. (An explanation of the procedures producing pain or distress in these animals and the reas such drugs were not used must be attached to this report	F. TOTAL NUMBER OF ANIMALS (COLUMNS C + D + E)
4. Dogs	64	422	170	145	737
5. Cats					
6. Guinea Pigs	19	84	153		237
7. Hamsters	66	371	584		955
8. Rabbits	33	412	88		500
9. Non-human Primates	306	894	62	35	991
10. Sheep					
11. Pigs					
12. Other Farm Animals					
13. Other Animals					

ASSURANCE STATEMENTS

1) Professionally acceptable standards governing the care, treatment, and use of animals, including appropriate use of anestetic, analgesic, and tranquilizing drugs, prior to, during, and following actual rese teaching, testing, surgery, or experimentation were followed by this research facility.

2) Each principal investigator has considered alternatives to painful procedures.

3) This facility is adhering to the standards and regulations under the Act, and it has required that exceptions to the standards and regulations be specified and explained by the principal investigator and ap Institutional Animal Care and Use Committee (IACUC). **A summary of all such exceptions is attached to this annual report.** In addition to identifying the IACUC-approved exceptions, this summary inc brief explanation of the exceptions, as well as the species and number of animals affected.

4) The attending veterinarian for this research facility has appropriate authority to ensure the provision of adequate veterinary care and to oversee the adequacy of other aspects of animal care and use.

CERTIFICATION BY HEADQUARTERS RESEARCH FACILITY OFFICIAL
(Chief Executive Officer or Legally Responsible Institutional Official)

SIGNATURE OF C.E.O. OR INSTITUTIONAL OFFICIAL	NAME & TITLE OF C.E.O. OR INSTITUTIONAL OFFICIAL (*Type or Print*)	DATE SIGNED
(b)(6), (b)(7)(c)		11/29/08

APHIS FORM 7023 (Replaces VS FORM 16-23 (OCT 88), which is obsolete.)
(AUG 91)

NOV 2 6 2008

CONFIDENTIAL

FACILITY SITES LISTING

Licensee/Registrant Name: **Wyeth Research**

Licensee/Registration Number: **23-R-0018**

Please list below all sites that house animals under the above registration number. Be sure to include all requested information. Do not leave any spaces blank. If the line does not apply, please mark it N/A. If you have more than 3 sites, please copy this form as many times as needed before filling in the sites.

Site No. 1	Name/Department:	(b)(2)High, (b)(7)(F)
	Address:	
	Floor/Room	
	Contact Person	(b)(6), (b)(7)(c)

Site No. 2	Name/Department:	(b)(2)High, (b)(7)(F)
	Address:	
	Floor/Room	
	Contact Person	(b)(6), (b)(7)(c)

Site No. 3	Name/Department:	(b)(2)High, (b)(7)f
	Address:	
	Floor/Room	
	Contact Person	(b)(6), (b)(7)(c)

Site No. 4	Name/Department:	(b)(2)High, (b)(7)(F)
	Address:	
	Floor/Room	
	Contact Person	(b)(6), (b)(7)(c)

Site No. 5	Name/Department:	(b)(2)High, (b)(7)f
	Address:	
	Floor/Room	
	Contact Person	(b)(6), (b)(7)(c)

Attachment to APHIS Form 7023
Column E Explanation for USDA Reporting Year
October 1, 2007 through September 30, 2008

Registration Number: 23-R-0018

(b)(2)High, (b)(7)f

Seventy-two (72) dogs were used in tests to assess the safety of new pharmaceuticals wherein unanticipated signs of gastrointestinal intolerability (emesis and or diarrhea) or one or more signs of organ system involvement (weight or body condition, cardiovascular signs, CNS signs, or anaphylaxis) were observed following dosing. All animals showing signs of pain or distress were attended by specially-qualified veterinary staff; and any animals with severe or chronic signs of pain or distress were provided appropriate veterinary medical care. Safety assessment studies are required for the approval of human pharmaceuticals by international drug regulatory authorities and the FDA (Food, Drug and Cosmetics Act, CFR Title 21). Prior to the conduct of these studies, the IACUC determined that no alternatives were available and that the minimum numbers of animals of the appropriate species were used, consistent with obtaining valid results. The IACUC approved the withholding of treatment to insure that unexpected interactions of the treatment with the test compound or the masking of clinical signs required for safety assessment did not occur. Either would interfere with the interpretation of results and possibly invalidate the study. Invalid studies would need to be repeated, requiring the use of additional animals.

Thirty-five (35) nonhuman primates were used in tests to assess the safety of new pharmaceuticals wherein unanticipated signs of gastrointestinal intolerability, cardiovascular signs, and CNS signs were observed following dosing. All animals showing signs of pain or distress were attended by specially-qualified veterinary staff; and any animals with severe or chronic signs of pain or distress were provided appropriate veterinary medical care. Safety assessment studies are required for the approval of human pharmaceuticals by international drug regulatory authorities and the FDA (Food, Drug and Cosmetics Act, CFR Title 21). Prior to the conduct of these studies, the IACUC determined that no alternatives were available and that the minimum numbers of animals of the appropriate species were used, consistent with obtaining valid results. The IACUC approved the withholding of treatment to insure that unexpected interactions of the treatment with the test compound or the masking of clinical signs required for safety assessment did not occur. Either would interfere with the interpretation of results and possibly invalidate the study. Invalid studies would need to be repeated, requiring the use of additional animals.

(b)(2)High, (b)(7)f

Two (2) dogs were used in tests to evaluate the effects of test compounds in a pacing-induced model of heart failure wherein the dogs reach a level of compensated heart failure.

All animals showing signs of pain or distress were attended by specially-qualified veterinary staff; and any animals with severe or chronic signs of pain or distress were provided appropriate veterinary medical care. Heart failure is a necessary requirement for this model in order to test compounds for efficacy prior to human clinical studies. The experimental compounds tested are designed to alleviate or reduce the heart failure induced in this model. Prior to the conduct of these studies, the IACUC determined that no alternatives were available and that the minimum numbers of animals of the appropriate species were used, consistent with obtaining valid results. The IACUC approved the withholding of treatment to insure that unexpected interactions of the treatment with the test compound or the masking of clinical signs required for safety assessment did not occur. Either would interfere with the interpretation of results and possibly invalidate the study. Invalid studies would need to be repeated, requiring the use of additional animals.

Thirty-two (32) dogs were used in tests to evaluate the efficacy of antiarrythmic compounds in an aseptic pericarditis model of atrial fibrillation wherein arrhythmia is produced. All animals showing signs of pain or distress were attended by specially-qualified veterinary staff; and any animals with severe or chronic signs of pain or distress were provided appropriate veterinary medical care. Test compounds are evaluated for their ability to eliminate or attenuate the atrial fibrillation that is induced in this model. Prior to the conduct of these studies, the IACUC determined that no alternatives were available and that the minimum numbers of animals of the appropriate species were used, consistent with obtaining valid results. The IACUC approved the withholding of treatment to insure that unexpected interactions of the treatment with the test compound or the masking of clinical signs required for safety assessment did not occur. Either would interfere with the interpretation of results and possibly invalidate the study. Invalid studies would need to be repeated, requiring the use of additional animals.

Thirty-nine dogs (39) were used in tests to evaluate the efficacy of antiarrythmic compounds in a pacing-induced model of atrial fibrillation wherein arrhythmia is produced. All animals showing signs of pain or distress were attended by specially-qualified veterinary staff; and any animals with severe or chronic signs of pain or distress were provided appropriate veterinary medical care. Test compounds are evaluated for their ability to eliminate or attenuate the atrial fibrillation that is induced in this model. Prior to the conduct of these studies, the IACUC determined that no alternatives were available and that the minimum numbers of animals of the appropriate species were used, consistent with obtaining valid results. The IACUC approved the withholding of treatment to insure that unexpected interactions of the treatment with the test compound or the masking of clinical signs required for safety assessment did not occur. Either would interfere with the interpretation of results and possibly invalidate the study. Invalid studies would need to be repeated, requiring the use of additional animals.

Attachment to APHIS Form 7023
IACUC-Approved Exceptions for USDA Reporting Year
October 1, 2007 through September 30, 2008

Registration Number: 23-R-0018

(b)(2)High, (b)(7)f

Eight (8) dogs were exempted from the provisions of 9 CFR§3.8 and the relevant facility Canine Exercise Plan. Animals dosed with radio-labeled test compound are required to be housed in special metabolism cages. While the metabolism cages meet the minimum housing requirements for dogs as defined in 9 CFR§3.6, they do not provide sufficient space to comply with exercise requirements. The exemption is contained in the IACUC-approved animal protocol, and the attending veterinarian or their designee documents each occurrence in the animal's clinical record.